Cargando…

Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling

AIMS/HYPOTHESIS: The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling. METHODS: Data were obtained from summary statistics of large-scale genome-wide association studies. We examined wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Karhunen, Ville, Daghlas, Iyas, Zuber, Verena, Vujkovic, Marijana, Olsen, Anette K., Knudsen, Lotte Bjerre, Haynes, William G., Howson, Joanna M. M., Gill, Dipender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563538/
https://www.ncbi.nlm.nih.gov/pubmed/34505161
http://dx.doi.org/10.1007/s00125-021-05564-7
_version_ 1784593424118185984
author Karhunen, Ville
Daghlas, Iyas
Zuber, Verena
Vujkovic, Marijana
Olsen, Anette K.
Knudsen, Lotte Bjerre
Haynes, William G.
Howson, Joanna M. M.
Gill, Dipender
author_facet Karhunen, Ville
Daghlas, Iyas
Zuber, Verena
Vujkovic, Marijana
Olsen, Anette K.
Knudsen, Lotte Bjerre
Haynes, William G.
Howson, Joanna M. M.
Gill, Dipender
author_sort Karhunen, Ville
collection PubMed
description AIMS/HYPOTHESIS: The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling. METHODS: Data were obtained from summary statistics of large-scale genome-wide association studies. We examined whether genetic associations for type 2 diabetes liability in the GIP and GIPR genes co-localised with genetic associations for 11 cardiometabolic outcomes. For those outcomes that showed evidence of co-localisation (posterior probability >0.8), we performed Mendelian randomisation analyses to estimate the association of genetically proxied GIP signalling with risk of cardiometabolic outcomes, and to test whether this exceeded the estimate observed when considering type 2 diabetes liability variants from other regions of the genome. RESULTS: Evidence of co-localisation with genetic associations of type 2 diabetes liability at both the GIP and GIPR genes was observed for five outcomes. Mendelian randomisation analyses provided evidence for associations of lower genetically proxied type 2 diabetes liability at the GIP and GIPR genes with lower BMI (estimate in SD units −0.16, 95% CI −0.30, −0.02), C-reactive protein (−0.13, 95% CI −0.19, −0.08) and triacylglycerol levels (−0.17, 95% CI −0.22, −0.12), and higher HDL-cholesterol levels (0.19, 95% CI 0.14, 0.25). For all of these outcomes, the estimates were greater in magnitude than those observed when considering type 2 diabetes liability variants from other regions of the genome. CONCLUSIONS/INTERPRETATION: This study provides genetic evidence to support a beneficial role of sustained GIP signalling on cardiometabolic health greater than that expected from improved glycaemic control alone. Further clinical investigation is warranted. DATA AVAILABILITY: All data used in this study are publicly available. The scripts for the analysis are available at: https://github.com/vkarhune/GeneticallyProxiedGIP. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05564-7.
format Online
Article
Text
id pubmed-8563538
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85635382021-11-04 Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling Karhunen, Ville Daghlas, Iyas Zuber, Verena Vujkovic, Marijana Olsen, Anette K. Knudsen, Lotte Bjerre Haynes, William G. Howson, Joanna M. M. Gill, Dipender Diabetologia Short Communication AIMS/HYPOTHESIS: The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling. METHODS: Data were obtained from summary statistics of large-scale genome-wide association studies. We examined whether genetic associations for type 2 diabetes liability in the GIP and GIPR genes co-localised with genetic associations for 11 cardiometabolic outcomes. For those outcomes that showed evidence of co-localisation (posterior probability >0.8), we performed Mendelian randomisation analyses to estimate the association of genetically proxied GIP signalling with risk of cardiometabolic outcomes, and to test whether this exceeded the estimate observed when considering type 2 diabetes liability variants from other regions of the genome. RESULTS: Evidence of co-localisation with genetic associations of type 2 diabetes liability at both the GIP and GIPR genes was observed for five outcomes. Mendelian randomisation analyses provided evidence for associations of lower genetically proxied type 2 diabetes liability at the GIP and GIPR genes with lower BMI (estimate in SD units −0.16, 95% CI −0.30, −0.02), C-reactive protein (−0.13, 95% CI −0.19, −0.08) and triacylglycerol levels (−0.17, 95% CI −0.22, −0.12), and higher HDL-cholesterol levels (0.19, 95% CI 0.14, 0.25). For all of these outcomes, the estimates were greater in magnitude than those observed when considering type 2 diabetes liability variants from other regions of the genome. CONCLUSIONS/INTERPRETATION: This study provides genetic evidence to support a beneficial role of sustained GIP signalling on cardiometabolic health greater than that expected from improved glycaemic control alone. Further clinical investigation is warranted. DATA AVAILABILITY: All data used in this study are publicly available. The scripts for the analysis are available at: https://github.com/vkarhune/GeneticallyProxiedGIP. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05564-7. Springer Berlin Heidelberg 2021-09-09 2021 /pmc/articles/PMC8563538/ /pubmed/34505161 http://dx.doi.org/10.1007/s00125-021-05564-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Karhunen, Ville
Daghlas, Iyas
Zuber, Verena
Vujkovic, Marijana
Olsen, Anette K.
Knudsen, Lotte Bjerre
Haynes, William G.
Howson, Joanna M. M.
Gill, Dipender
Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
title Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
title_full Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
title_fullStr Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
title_full_unstemmed Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
title_short Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
title_sort leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563538/
https://www.ncbi.nlm.nih.gov/pubmed/34505161
http://dx.doi.org/10.1007/s00125-021-05564-7
work_keys_str_mv AT karhunenville leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT daghlasiyas leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT zuberverena leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT vujkovicmarijana leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT olsenanettek leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT knudsenlottebjerre leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT hayneswilliamg leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT howsonjoannamm leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling
AT gilldipender leveraginghumangeneticdatatoinvestigatethecardiometaboliceffectsofglucosedependentinsulinotropicpolypeptidesignalling